miR-145 micelles mitigate atherosclerosis by modulating vascular smooth muscle cell phenotype

Chin, Deborah; Poon, Christopher; Wang, Jonathan; Joo, Johan; Ong, Venetia; Jiang, Zhangjingyi; Cheng, Kayley; Plotkin, Anastasia; Magee, Gregory A.; Chung, Eun Ji

doi:10.1016/j.biomaterials.2021.120810

Cited by 74 publications

(60 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with free miR-145 or PBS, the miR-145 micelles effectively mitigated atherosclerosis development by inhibiting plaque-propagating cell types derived from VSMCs. 156 This experiment indicated that miR-145 micelles prevented lesion growth by 49% and 35% in early-stage and mid-stage atherosclerosis, respectively.…”

Section: Nanotechnology Approaches For Therapy Of Cadsmentioning

confidence: 90%

Nanotechnology for cardiovascular diseases

Fang

et al. 2022

The Innovation

View full text Add to dashboard Cite

Section: Nanotechnology Approaches For Therapy Of Cadsmentioning

confidence: 90%

Nanotechnology for cardiovascular diseases

Fang

et al. 2022

The Innovation

View full text Add to dashboard Cite

“…Another study utilized a novel nanoparticles technology to ensure that miR-145 was precisely transfected into VSMCs, namely the miR-145 micelles. To figure out its therapeutic effect, both an early-stage and an advanced-stage atherosclerotic ApoE −/− mice were treated with the miR-145 micelles, resulting in the inhibition of phenotype switching of VSMCs and preventing atherosclerotic progression ( 61 ).…”

Section: Non-coding Rnas In Vascular Smooth Muscle Cellsmentioning

confidence: 99%

Non-coding RNA-Associated Therapeutic Strategies in Atherosclerosis

Tang

Chen

2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Atherosclerosis has been the main cause of disability and mortality in the world, resulting in a heavy medical burden for all countries. It is widely known to be a kind of chronic inflammatory disease in the blood walls, of which the key pathogenesis is the accumulation of immunologic cells in the lesion, foam cells formation, and eventually plaque rupture causing ischemia of various organs. Non-coding RNAs (ncRNAs) play a vital role in regulating the physiologic and pathophysiologic processes in cells. More and more studies have revealed that ncRNAs also participated in the development of atherosclerosis and regulated cellular phenotypes such as endothelial dysfunction, leukocyte recruitment, foam cells formation, and vascular smooth muscle cells phenotype-switching and apoptosis. Given the broad functions of ncRNAs in atherogenesis, they have become potential therapeutic targets. Apart from that, ncRNAs have become powerful blueprints to design new drugs. For example, RNA interference drugs were inspired by small interfering RNAs that exist in normal cellular physiologic processes and behave as negative regulators of specific proteins. For instance, inclisiran is a kind of RNAi drug targeting PCKS9 mRNA, which can lower the level of LDL-C and treat atherosclerosis. We introduce some recent research progresses on ncRNAs related to atherosclerotic pathophysiologic process and the current clinical trials of RNA drugs pointed at atherosclerosis.

show abstract

“…Vascular smooth muscle cells [113] Disulfide cross-linked micelles Colon cancer cells [114] Nanocapsules Colorectal cancer cells [115] PLGA NPs Vascular smooth muscle cells [116] Chitosan-thiolated dextran NPs Cancer cells [117,118] Magnetic nanoformulation Pancreatic cancer [119] Polyarginine-disulfide-linked PEI NPs Prostate cancer [120] GNPs Prostate and breast cancer cells [121] HA-PLGA/PEI with miR-145 expression plasmid Colon carcinoma [122] Chitosan polyplex NPs with miR-145 expression plasmid MCF-7 [123] miR-182 PEGylated GNP nanogel Metastatic breast cancer [124] PEGylated GNPs Glioblastoma [125] miR-34a, miR-137, miR-144 and miR-182 GNPs UM cells [126] To suppress the function of oncomiR miR-21, several studies have investigated the anti-cancer efficacy of the anti-miR-21 oligonucleotide loaded in (1) AS1411 anti-nucleolin aptamer-decorated PEGylated PLGA NPs, (2) acid-triggered charge-reversible graphenebased NPs with multilayer polymers, (3) GNPs and (4) chlorotoxin-coupled stable nucleic acid lipid NPs and three-way-junction (3WJ)-based RNA NPs for targeting various types of cancers [104][105][106][107][108]. Of note, the 3WJ core derived from packaging the RNA of the bacteriophage phi29 DNA packaging motor has been extensively studied to fabricate various RNA NPs [127].…”

Section: Micellesmentioning

confidence: 99%

“…The miR-142-3p mimic was loaded in G5 PAMAM dendrimers to target myeloid cells [112]. Because the tumor suppressor miR-145 inhibits multiple types of tumor cells, numerous nanocarriers have been developed for miR-145 mimic delivery [113][114][115][116][117][118][119][120][121], including micelles, protamine nanocapsules, PLGA NPs, redox-responsive chitosan-thiolated dextran NPs, magnetic NPs, polyarginine-disulfidelinked PEI NPs and GNPs. Additionally, miR-145 expression vectors carried by HA-PLGA/PEI NPs and chitosan polyplex NPs have been delivered into cancer cells and found to restore miR-145 expression levels [122,123].…”

Section: Micellesmentioning

confidence: 99%

Potential of miRNA-Based Nanotherapeutics for Uveal Melanoma

Yang

Wang

Hardy

2021

Cancers

View full text Add to dashboard Cite

Uveal melanoma (UM) is the most common adult intraocular cancer, and metastatic UM remains deadly and incurable. UM is a complex disease associated with the deregulation of numerous genes and redundant intracellular signaling pathways. As understanding of epigenetic dysregulation in the oncogenesis of UM has increased, the abnormal expression of microRNAs (miRNAs) has been found to be an epigenetic mechanism underlying UM tumorigenesis. A growing number of miRNAs are being found to be associated with aberrant signaling pathways in UM, and some have been investigated and functionally characterized in preclinical settings. This review summarizes the miRNAs with promising therapeutic potential for UM treatment, paying special attention to the therapeutic miRNAs (miRNA mimics or inhibitors) used to restore dysregulated miRNAs to their normal levels. However, several physical and physiological limitations associated with therapeutic miRNAs have prevented their translation to cancer therapeutics. With the advent of nanotechnology delivery systems, the development of effective targeted therapies for patients with UM has received great attention. Therefore, this review provides an overview of the use of nanotechnology drug delivery systems, particularly nanocarriers that can be loaded with therapeutic miRNAs for effective delivery into target cells. The development of miRNA-based therapeutics with nanotechnology-based delivery systems may overcome the barriers of therapeutic miRNAs, thereby enabling their translation to therapeutics, enabling more effective targeting of UM cells and consequently improving therapeutic outcomes.

show abstract

miR-145 micelles mitigate atherosclerosis by modulating vascular smooth muscle cell phenotype

Cited by 74 publications

References 49 publications

Nanotechnology for cardiovascular diseases

Nanotechnology for cardiovascular diseases

Non-coding RNA-Associated Therapeutic Strategies in Atherosclerosis

Potential of miRNA-Based Nanotherapeutics for Uveal Melanoma

Contact Info

Product

Resources

About